Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypocupremia and bone marrow failure.

A S Haddad1, V Subbiah, A E Lichtin

  • 1Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, R40, Cleveland, Ohio 44195 USA.

Haematologica
|January 2, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Exploring the pathway: clinical utility and open challenges of targeting BRAF alterations in biliary tract cancers and gastrointestinal malignancies.

ESMO gastrointestinal oncology·2026
Same author

ROME trial wasn't built in a day: the decade-long journey to randomized evidence in precision oncology.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.

ESMO open·2025
Same author

All roads lead to ROME: convergence of evidence in precision oncology.

ESMO open·2025
Same author

BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.

ESMO open·2025
Same journal

<i>Erratum</i> to: "Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial".

Haematologica·2026
Same journal

Introduction to the Review Series. Chronic myeloid leukemia in 2026.

Haematologica·2026
Same journal

Metformin: interferon's new dancing partner?

Haematologica·2026
Same journal

A potent and manipulable graft-<i>versus</i>-leukemia effect underpins the increasingly important role of transplantation in acute myeloid leukemia.

Haematologica·2026
Same journal

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Haematologica·2026
Same journal

Academic point-of-care anti-CD19 CAR T-cell therapy induces durable remission and transient paroxysmal nocturnal hemoglobinuria-type cell expansion in a patient with multi-refractory immune thrombocytopenia.

Haematologica·2026
See all related articles

Copper deficiency can cause bone marrow failure and cytopenias, often overlooked conditions. Early diagnosis through serum copper testing is crucial for successful treatment and recovery.

Area of Science:

  • Hematology
  • Nutritional Science
  • Medical Diagnostics

Background:

  • Copper deficiency is primarily known for neurological complications.
  • Its role in causing bone marrow failure and cytopenias is underrecognized.
  • Hypocupremia can present with hematological abnormalities mimicking other bone marrow failure syndromes.

Observation:

  • Presents three cases of bi-lineage cytopenia linked to copper deficiency.
  • Analyzes clinical features from current and historical cases.
  • Highlights the importance of clinical suspicion for diagnosing copper deficiency.

Findings:

  • Copper deficiency can manifest as significant bone marrow failure.
  • Bi-lineage cytopenias are a key indicator of this deficiency.

Related Experiment Videos

  • Serum copper level testing is essential for diagnosis.

    • Implications:

    • Suggests including copper deficiency in the differential diagnosis for reversible bone marrow failure.
    • Emphasizes prompt diagnosis and treatment of hypocupremia to prevent irreversible bone marrow damage.
    • Highlights the need for increased awareness among clinicians regarding hematological manifestations of copper deficiency.